Matricelf

Matricelf has developed a technology that enables the production of autologous engineered tissue composed of matrix and cells derived from patients omental biopsies. In 2019, Matricelf licensed the technology that enabled scientists at Tel Aviv university to 3D print a human heart from human cells and matrix for the first time in history. Matricelfs proprietary decellularization process separates stromal cells and extracellular matrix (ECM) from a small omental biopsy sample. A thermo-responsive hydrogel is produced from the ECM, and the stromal cells are reprogrammed into induced pluripotent stem cells (iPSCs) which are then incorporated into the hydrogel before being differentiated into the desired functional tissue using Matricelfs patent-pending methodology. When combined with motor neurons, Matricelfs proprietary hydrogel creates functional spinal cord implants that can bridge injured spinal cord tissue. The companys novel regenerative medicine platform aims to cure a range of medical conditions, including spinal cord injuries, age-related macular degeneration, Parkinsons disease, myocardial infarction, and others.

Matricelf has raised $10.04M in total funding across 4 rounds. The company is currently at the Public stage. Key investors include Magna Capital Partners, Undisclosed Investor(s).

Matricelf was founded in 2019 by Alon Sinai (Co-founder & CEO).

Matricelf operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Biomaterials & Tissue Engineering, with core technologies in Materials & Substances, Implants, Biologicals, Cells. Target customers: Healthcare & Life Sciences, Healthcare, Providers, Life Sciences, Biotechnology, Pharmaceuticals.

Matricelf is based in Golda Me'ir St 3, Ness Ziona, Israel, Center District.